-
公开(公告)号:US20120258039A1
公开(公告)日:2012-10-11
申请号:US13367178
申请日:2012-02-06
申请人: Daniela Gast , Peter Altevogt , Gerhard Moldenhauer , Frank Brietling , Achim Krüger , Silke Wolterink , Sandra Lüttgau , Ulrich Mõbius , Yi Li
发明人: Daniela Gast , Peter Altevogt , Gerhard Moldenhauer , Frank Brietling , Achim Krüger , Silke Wolterink , Sandra Lüttgau , Ulrich Mõbius , Yi Li
IPC分类号: A61K39/395 , A61M37/00 , A61N5/10 , A61K51/10 , A61P35/00
CPC分类号: C07K16/2803 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/02 , A61N5/0613 , A61N5/10 , A61N2005/0661 , A61N2005/1087 , A61N2005/1089 , C07K2317/24 , C07K2317/41 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N33/57492
摘要: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
摘要翻译: 本发明涉及抗L1单克隆抗体9.3以及相关抗体或结合分子,以及其用途,特别是在肿瘤治疗中。
-
公开(公告)号:US20090162355A1
公开(公告)日:2009-06-25
申请号:US12139006
申请日:2008-06-13
申请人: Daniela Gast , Peter Altevogt , Gerhard Moldenhauer , Frank Brietling , Achim Kruger , Silke Wolterink , Sandra Luttgau , Ulrich Mobius , Yi Li
发明人: Daniela Gast , Peter Altevogt , Gerhard Moldenhauer , Frank Brietling , Achim Kruger , Silke Wolterink , Sandra Luttgau , Ulrich Mobius , Yi Li
IPC分类号: A61K39/395 , C07K16/18 , C12N5/06
CPC分类号: C07K16/2803 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/02 , A61N5/0613 , A61N5/10 , A61N2005/0661 , A61N2005/1087 , A61N2005/1089 , C07K2317/24 , C07K2317/41 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N33/57492
摘要: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
摘要翻译: 本发明涉及抗L1单克隆抗体9.3以及相关抗体或结合分子,以及其用途,特别是在肿瘤治疗中。
-
公开(公告)号:US20080299123A1
公开(公告)日:2008-12-04
申请号:US11868278
申请日:2007-10-05
IPC分类号: A61K39/395 , C07K16/18 , C07H21/02 , A61K31/711 , A61K33/24 , A61K31/7105 , C07H21/04
CPC分类号: C07K14/70503 , A61K2039/505 , C07K16/2803 , C07K2317/73 , C07K2317/76 , C12N15/1138 , C12N2310/14
摘要: The present invention relates to the use of L1 interfering molecules, especially anti-L1 antibodies, in tumor treatment. Especially, the present invention relates to the use of said L1 interfering molecules in sensitizing tumor cells for the treatment with chemotherapeutic drugs of with radiotherapy and to the combined administration of L1 interfering molecules with chemotherapeutic drugs or with radiotherapy.
摘要翻译: 本发明涉及L1干扰分子,特别是抗L1抗体在肿瘤治疗中的应用。 特别地,本发明涉及所述L1干扰分子在使肿瘤细胞敏化用于放射治疗的化学治疗药物以及将L1干扰分子与化学治疗药物或放射疗法联合给药时的用途。
-
公开(公告)号:US20080003222A1
公开(公告)日:2008-01-03
申请号:US11573269
申请日:2005-07-27
申请人: Peter Altevogt , Daniela Gast , Maina Fogel
发明人: Peter Altevogt , Daniela Gast , Maina Fogel
IPC分类号: A61K31/7088 , A61K38/16 , A61K39/395 , A61P35/00 , C12Q1/68 , G01N33/566
CPC分类号: C12N9/6489 , C07K14/70503
摘要: Described is a pharmaceutical composition comprising a compound(s) interfering with the biological activity of L1 and/or ADAM10 or their expression. Also described is the use of said compound(s) for the prevention/treatment of carcinomas like ovarian and endometrial carcinoma. Finally, the diagnosis of highly malignant forms of carcinomas which is based on the determination of the activity/expression of L1 and/or ADAM10 is described.
摘要翻译: 描述了包含干扰L1和/或ADAM10的生物学活性或其表达的化合物的药物组合物。 还描述了所述化合物用于预防/治疗诸如卵巢和子宫内膜癌的癌症的用途。 最后,描述了基于L1和/或ADAM10的活性/表达的确定的高度恶性形式的癌症的诊断。
-
-
-